Shenyi Capsule In Combination With Paclitaxel And Carboplatin In Clinical Observation And Treatment Of Ovarian Cancer

Objective: Observe the efficacy,side effects of chemotherapy and the impact onquality of life of Shenyi Capsule combined with paclitaxel and carboplatin in ovariancancer.Methods: Selected103cases of ovarian cancer chemotherapy patients were randomlydivided into experimental group and control group.The program is paclitaxel andcarboplatin chemotherapy. There are55people in control group,which all usechemotherapy drugs only.And there48people in experimental group,which ueschemotherapy drugs and Shenyi Capsule at the same time.The way of taking ShenyiCapsule is2times a day, each20mg, half an hour before meals, warm water, last for eightweeks. The study is monitored for eight weeks each.Observe changes of two groups inshort-term effect, white blood cells,platelets,alanine aminotransferase or aspartateaminotransferase, nausea,vomiting,diarrhea,peripheral nerve adverse reactions and qualityof life. The short-term effect is evaluated by the RECIST1.1.Take umor12andCT(measure the longest diameter of all target lesions) examination before the first courseof chemotherapy, at the end of the second course of chemotherapy and4weeks after thesecond course of chemotherapy.The Side effects of chemotherapy are evaluated by WHOchemotherapy side effects classification standard.Test routine analysis of blood and liverfunction before each chemotherapy,the5th,6th,7th day after the end of chemotherapy.Finally,select the minimum of white blood cells and platelets,the maximum of alanineaminotransferase or aspartate aminotransferase in8weeks for statistics. Nausea, vomiting,diarrhea and peripheral nerve adverse reactions are evaluated one time a week andselected the most severe classification for statistics. Quality of life is evaluated by KPS atthe start and end of the experiment.Use SPSS13.0for statistical analysis. Descriptivestatistics were used to analyze.Parametric tests use the chi-square goodness of fit test, nonparametric test use rank sum test, two-tailed significance level of α=0.05. P<0.05isconsidered statistically significance.Results:To compare with the experimental group and the control group in the totaleffective rate has no statistically significant(P=0.109),but the clinical benefit rate hasstatistically significant(P=0.040).Adverse reactions in the experimental group of whiteblood cells, platelets decreased rate of alanine aminotransferase or aspartateaminotransferase increased rate, nausea and vomiting are lower than that in the controlgroup,which has statistically significant highly（P=0.006、P<0.001、P<0.001、P<0.001）.Diarrhea, peripheral nerve symptoms in the experimental group and the control groupshows no significant difference(P=0.059、P=0.276).Patients in the experimental group areimproved the quality of life higher than the control group, the difference is statisticallysignificant(P=0.001).Conclusion: Shenyi Capsule combined with paclitaxel, carboplatin treatment ofovarian cancer can enhance the efficacy of chemotherapy drugs，reduce the side effects ofchemotherapy drugs partly,such as myelosuppression, liver damage, nausea and vomitingsymptom,and also can improve quality of life. Shenyi Capsule combined with paclitaxel,carboplatin treatment of ovarian cancer is safe and effective.It is worth to be an adjuvantchemotherapy drug in clinical practice.